All In Biotech

Drug Trial Radar · NCT07672769

Bexmarilimab + Azacitidine Versus Placebo + Azacitidine in Participants With Treatment-naïve Higher-risk Myelodysplastic Syndromes

Bexmarilimab Plus Azacitidine in a Randomized, Double-blind, Placebo-controlled Phase IIb Trial in Treatment-naïve Higher-risk Myelodysplastic Syndromes (HR-MDS)

Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

90

Planned (sponsor's estimate)

Start

Nov 2026

Primary completion

Nov 2027

Study completion Dec 2030

Sponsor

Lead sponsor
Faron Pharmaceuticals LtdIndustry
Sponsor type
Industry
First posted
Jun 29, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase IIb study (BEXERA) will evaluate the safety and efficacy of bexmarilimab (FP-1305), an antibody targeting Clever-1, given in combination with azacitidine compared with azacitidine plus placebo in adults with treatment-naïve higher-risk myelodysplastic syndromes (HR-MDS). Participants will be randomized to receive bexmarilimab at one of two dose levels (1 mg/kg or 3 mg/kg) plus azacitidine, or placebo plus azacitidine. The primary aim is to select the recommended dose of bexmarilimab for subsequent development based on a predefined integration of clinical response and safety/tolerability.

Conditions

  • Higher Risk Myelodysplastic Syndromes

Interventions

  • bexmarilimab (1mg/kg)Drug

    1mg/kg. Administered weekly (Q1W) with the opportunity to reduce frequency to biweekly (Q2W) based on time on treatment and disease response. Intravenous (IV) administration

  • azacitidineDrug

    Standard of care medication, administered per institutional guidelines/label

  • PlaceboDrug

    Participants will receive saline placebo, prepared by the local site pharmacy to match bexmarilimab at point of dispensation. Administered on a schedule to match bexmarilimab

  • bexmarilimab (3mg/kg)Drug

    3mg/kg. Administered weekly (Q1W) with the opportunity to reduce frequency to biweekly (Q2W) based on time on treatment and disease response. Intravenous (IV) administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose selection utility score utilising efficacy and safety components.Time frame: 3-4 months from last participant enrollment

Locations

35 sites in 7 countries. Site status is shown where the registry gives one.

  • City of Hope Medical Center

    Duarte, California · Recruiting

  • University of Colorado Cancer Center

    Aurora, Colorado · Not yet recruiting

  • Yale Cancer Center

    New Haven, Connecticut · Not yet recruiting

  • Moffitt Malignant Hematology & Cellular Therapy at Memorial Healthcare System

    Pembroke Pines, Florida · Not yet recruiting

  • Mass General Brigham Cancer Institute

    Boston, Massachusetts · Not yet recruiting

  • University of North Carolina Lineberger Comprehensive Cancer Center

    Chapel Hill, North Carolina · Not yet recruiting

  • Vanderbilt University Medical Center

    Nashville, Tennessee · Not yet recruiting

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas · Not yet recruiting

  • Medical College of Wisconsin - Clinical Cancer Center - Froedtert Hospital

    Milwaukee, Wisconsin · Not yet recruiting

  • Fakultní nemocnice Brno

    Brno, Czechia · Not yet recruiting

  • Fakultní nemocnice Hradec Králové

    Hradec Králové, Czechia · Not yet recruiting

  • Fakultni nemocnice Ostrava

    Ostrava-Poruba, Czechia · Not yet recruiting

  • Ustav hematologie a krevni transfuze

    Prague, Czechia · Not yet recruiting

  • Vseobecna fakultni nemocnice v Praze

    Prague, Czechia · Not yet recruiting

  • Helsinki University Hospital Comprehensive Cancer Center

    Helsinki, Finland · Not yet recruiting

  • Oulu University Hospital

    Oulu, Finland · Not yet recruiting

  • Tampere University Hospital

    Tampere, Finland · Not yet recruiting

  • Turku University Hospital

    Turku, Finland · Not yet recruiting

  • CHU de Bordeaux

    Bordeaux, France · Not yet recruiting

  • Hôpital Saint-Louis

    Paris, France · Not yet recruiting

  • CHU de Poitiers

    Poitiers, France · Not yet recruiting

  • The Institut Gustave Roussy

    Villejuif, France · Not yet recruiting

  • AOU SS. Antonio e Biagio e Cesare Arrigo

    Alessandria, Italy · Not yet recruiting

  • IRCCS Azienda Ospedaliero-Universitaria di Bologna

    Bologna, Italy · Not yet recruiting

  • INOC - Istituto Nazionale Oncologico Candiolo

    Candiolo, Italy · Not yet recruiting

  • IRCCS Istituto Europeo di Oncologia

    Milan, Italy · Not yet recruiting

  • Pratia Onkologia Katowice

    Katowice, Poland · Not yet recruiting

  • Aidport Clinical Trials Hospital

    Skórzewo, Poland · Not yet recruiting

  • MTZ Clinical Research Powered by Pratia

    Warsaw, Poland · Not yet recruiting

  • University Hospital Birmingham Nhs Trust

    Birmingham, United Kingdom · Not yet recruiting

  • The Beatson West of Scotland Cancer Centre

    Glasgow, United Kingdom · Not yet recruiting

  • Royal Cornwall Hospitals NHS Trust

    Truro, United Kingdom · Recruiting

  • King's College Hospital

    London, Greater London, United Kingdom · Recruiting

  • The Christie NHS Foundation Trust

    Manchester, Greater Manchester, United Kingdom · Recruiting

  • Maidstone and Tunbridge Wells NHS Trust

    Maidstone, Kent, United Kingdom · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.